AzTrials
AzTrials

Ophthalmic SurgeryNCT05901753

A Comparative Study Between Laryseal Pro Supra Glottic Device (SGD) With Proseal Laryngeal Mask Airway

A study testing Laryseal pro supra glottic device and Laryngeal Mask Airway- Proseal™ in people with Ophthalmic Surgery, run by Kasr El Aini Hospital at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Difficult airway is a nightmare to every anesthetist. Over the last decade, several supraglottic airway devices appeared in the clinical field as an alternative to the more invasive endotracheal intubation(1). Read more about this study

Who is it for?
Ages 18 to 60 yearsHealthy volunteers can take part
Conditions the study is for
Ophthalmic Surgery
What is being tested?
Laryseal pro supra glottic device and Laryngeal Mask Airway- Proseal™
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
1 siteEgypt
Study dates
13 Jun 2023to 6 Nov 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Both males and females
  • Age 18-60 years
  • GANZOURI airway scores less than 4
  • Patients undergoing ophthalmic surgeries not exceeding two hours under general anesthesia (cataract surgery,glaucoma surgery, corneal transplant, strabismus surgery

Who cannot join

  • Patients have risks of gastric aspiration (patients known to have gastro esophageal reflux disease (GERD), hiatus hernia or previous upper gastrointestinal tract surgery)
  • patients have respiratory or pharyngeal pathology
  • morbidly obese patients with body mass index >40 kg/m3

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Kasr Alainy, Cairo University

    Cairo, 202

Other trials in Egypt

About this study

Official title: A Comparative Study Between Laryseal Pro Supra Glottic Device (SGD) With Proseal Laryngeal Mask Airway Regarding Clinical Performance in Patients Undergoing Ophthalmic Surgery. A Prospective Randomized Control Study

Difficult airway is a nightmare to every anesthetist. Over the last decade, several supraglottic airway devices appeared in the clinical field as an alternative to the more invasive endotracheal intubation(1). However, many anesthetists found themselves unaccustomed with the newly invented devices .Supraglottic airway devices (SAD) have become valuable for both routine and difficult airway management. After the creation of the laryngeal mask airway (LMA) classic in the 1980s, there has been a steady increase in the applications for use of supraglottic airways. Developed by Dr. Archie Brain in 2000, the ProSeal laryngeal mask airway (P-LMA) is a second-generation supraglottic airway device (SAD) with two lumens separating the alimentary and respiratory channels from each other This study aim to compare the use of the Laryseal Pro and the Proseal LMA as a supraglottic devices by measuring the time of insertion (which is defined as time interval in seconds between removing the ventilation mask and picking the device up till connecting to the ventilator and appearance of the first wave on the capnogram)

Objectives:

Read more

To determine ease of insertion for each supra glotic device. To Estimate the time needed for insertion for each supra glotic device. To identify airway pressure leakage, gastric tube insertion success and complication for each device.

It is hypothesized that the Laryseal pro is a safe superior supraglottic airway device and its insertion is easier than the LMA-Proseal .

Read the detailed description

This a randomized control trial is designed to include (120) patients ASA physical status I ,II patients ranging from(18) to(60)years old scheduled for ophthalmic surgery

Patients meeting the inclusion criteria will be randomly assigned to receive either:

Group A: Laryseal pro supra glottic device (SGD) (n=60) Group B: Laryngeal Mask Airway- Proseal™ (n=60) Anesthesia management

Preoperative procedures:

After being accepted into the study, participants age, gender, weight, medications and any other co morbidities will be collected. patients will be allowed to fast for 6-8 h before surgery.

After securing IV access by 20G cannula, all patients will receive 0.05mg/kg midazolam for anxiety. Ranitidine 50mg, metoclopramide 10mg and intravenous atropine 0.01 mg/kg as a premedication. Routine monitoring devices will be installed (basline blood pressure, heart rate, and pulse oximetry data) Proper airway assessment of the patients will be done according to El-Ganzouri Airway Scoring System(13) Intraoperative monitoring includes ASA standard monitoring Electrocardiography (ECG), noninvasive blood pressure, pulse oximetry for O2 saturation, end-tidal CO2 values by capnography

Intraoperative procedures:

Induction of general anaesthesia will be achieved by approximate doses according to ideal body weight of Fentanyl 1ug/kg, Propofol 2mg/kg and Atracurium 0.5mg/kg and Lidocaine 1mg/kg , 3 minutes of for oxygenation and mask ventilation before device insertion .

Anesthesia maintenance will be achieved with the randomly assigned supraglottic device for each group which will be inserted and reconnected to the ventilator circuit., 2 minumium alveolar concentration of sevoflurane, volume-controlled mode ventilation, respiratory rate will be adjusted according to Et CO2 to range between 35-40 mmHg, a tidal volume of 6-8 ml/kg and mixture of gases in proportion 50% oxygen and 50% air

The LMA-Proseal™ will be inserted using the digit method. The size will be determined according to the patient's weight and inserted according to the manufacture's recommendation (12) with the use of an introducer. The cuff will be inflated with air and the cuff's pressure will be adjusted to 70 mmHg using a cuff pressure manometer. the device will be lubricated well on both sides, head and neck were placed in neutral position, the proximal firmer part of the device will be compressed between the thumb and two fingers and advanced toward hard and soft palate, the tab will be pulled slightly if needed to increase curvature of the device for better fitting, the device will be advanced till resistance felt.

For Laryseal pro SGD, the jaw will be lifted during insertion and the head will be extended, proper lubrication of both the front and back of the laryseal pro as if the patient's mouth is dry the laryseal pro ridges can get hung up on the back of the tongue during placement. The laryseal pro SP will be advanced at a forward angle aiming for the back of the tongue and soft palate. Then the colored connector will be pushed by index finger till feeling resistance . Device insertion will be considered successful by observing bilateral chest wall movement as well as a stable square-wave capnogram trace. Failed device placement will be defined as being unable to observe a smooth square-wave capnograph, inadequate ventilation, no rise of the chest wall, and significant leakage from the gastric drain tube If, after two attempts, the device not properly inserted, endotracheal intubation will be done and those patients will be excluded from the study.

Insertion time of the study device will be recorded for each device which is defined as time interval between picking the device up till appearance of the first wave on the capnogram.

The ease of insertion will be classified based on insertion attempts (1 = first attempt, 2 = second attempt, 3 = third attempt, 4 = impossible) The vital signs(heart rate and mean blood pressure) will be recorded; just prior to device insertion (T1); after connection to capnography (T2), to assess the pressor response during device insertion The airway seal pressure will be assessed for each device , measured with head in the neutral position, under manual ventilation by closing the adjustable pressure-limiting (APL) valve to 30 cmH2O adjustable pressure-limiting (APL) valve to 30 cmH2O at a fixed gas flow of 3 L.min-1 , 7, and observing of the rise of the ventilator's airway pressure[14]. A "puffing" sound will be heard near the patient's mouth (release of pressure) indicating the airway seal pressure.

Once patients reconnected to the ventilator circuit, a gastric tube will be introduced through the integrated drainage channel present in both devices. To standardize the technique, the same brand gastric tube will be used for both devices. The success rate of its insertion will be recorded. Ease of gastric tube insertion will be graded on a three-point scale (1 = first attempt, 2 = second attempt and 3 = impossible). After venting the stomach the blocker will be introduced and inflated to achieve proper sealing. The surgery will be allowed to proceed after ensuring proper positioning and sealing of the device.

At the end of surgery, adequate reversal of residual neuromuscular blockade will be achieved The device will be removed and checked for any blood streaked mucous as a sign of airway trauma. Post-operative sore throat or hoarseness of voice will be assessed at 0, 2 and 4 h. Any regurgitation , pulmonary aspiration, bronchospasm , hypoxemia will be also recorded.

Being tested
Laryseal pro supra glottic device, Laryngeal Mask Airway- Proseal™

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Laryseal pro supra glottic deviceDevice

    Also called supra glottic device

    The laryseal pro SP will be advanced at a forward angle aiming for the back of the tongue and soft palate. Then the colored connector will be pushed by index finger till feeling resistance . Device insertion will be considered successful by observing bilateral chest wall movement as well as a stable square-wave capnogram trace

  • Laryngeal Mask Airway- Proseal™Device

    Also called supra glottic device

    The cuff will be inflated with air and the cuff's pressure will be adjusted to 70 mmHg using a cuff pressure manometer. the device will be lubricated well on both sides, head and neck were placed in neutral position, the proximal firmer part of the device will be compressed between the thumb and two fingers and advanced toward hard and soft palate, the tab will be pulled slightly if needed to increase curvature of the device for better fitting, the device will be advanced till resistance felt.

Study groups in NCT05901753
Study groupRoleWhat they receive
Laryseal pro supra glottic device (SGD)ExperimentalLaryseal pro SGD, the jaw will be lifted during insertion and the head will be extended, proper lubrication of both the front and back of the laryseal pro as if the patient's mouth is dry the laryseal pro ridges can get hung up on the back of the tongue during placement.
Receives: Device: Laryseal pro supra glottic device
Laryngeal Mask Airway- Proseal™ExperimentalThe LMA-Proseal™ will be inserted using the digit method. The size will be determined according to the patient's weight and inserted according to the manufacture's recommendation with the use of an introducer.
Receives: Device: Laryngeal Mask Airway- Proseal™

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The time of insertion of supra glottic device

    time interval between picking the device up till appearance of the first wave on the capnogram

    Measured: time interval between picking the device up till appearance of the first wave on the capnogram. (seconds)

Secondary outcomes (1)
  1. complications

    Blood on device after removal, vomiting, aspiration, bronchospasm and Post-operative sore throat or hoarseness of voice

    Measured: it will be measured postoperatively at 0, 3, 6 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jun 2023
  2. Study start13 Jun 2023
  3. Primary completion6 Nov 2023
  4. Study completion6 Nov 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
120 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05901753
Sponsor's protocol ID
MS-631-2022
Status last verified
Nov 2023
First submitted
5 Jun 2023
Last updated
7 Nov 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Laryseal pro supra glottic device and Laryngeal Mask Airway- Proseal™ in people with Ophthalmic Surgery, run by Kasr El Aini Hospital at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The time of insertion of supra glottic device (time frame: time interval between picking the device up till appearance of the first wave on the capnogram. (seconds)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Nov 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in